Repligen Corporation (RGEN)Healthcare | Medical Instruments & Supplies | Waltham, United States | NasdaqGS
175.42 USD
+2.91
(1.687%)
⇧
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 175.42 |
Hot Take ↕ | Oct. 10, 2026, 8:27 a.m. EDT
The BioLife acquisition is the defining catalyst here, signaling a strategic pivot toward cell therapy that could unlock significant value over time. However, the stock is currently priced for perfection with a trailing P/E exceeding 230x and a return on equity barely above 2%, which creates a substantial valuation gap between current reality and future potential. While the price has stabilized above the fifty-day moving average following a sharp pullback, the options market is hedging against further downside while betting on a distant upside target. Investors should view this as a high-risk, high-reward growth play rather than a value opportunity, watching closely for execution on the new business line to justify the premium. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.187031 |
| AutoETS | 0.259429 |
| AutoARIMA | 0.259430 |
| MSTL | 0.272665 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 1.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.229 |
| Excess Kurtosis | -0.25 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 32.715 |
| Revenue per Share | 13.936 |
| Market Cap | 11,137,479,680 |
| Trailing P/E | 240.30 |
| Forward P/E | 66.01 |
| Beta | 1.08 |
| Profit Margins | 5.29% |
| Website | https://www.repligen.com |
As of Oct. 10, 2026, 8:27 a.m. EDT: Speculators are positioning for a wider range of outcomes. Call buyers are establishing a significant wall of open interest at the $250 strike for November expiration, suggesting a bullish target well above current levels. Conversely, put buyers are heavily concentrated at lower strikes ($110-$120) for November and December, indicating a desire for downside protection. Implied volatility remains elevated across expirations, reflecting uncertainty around the recent price correction and the integration of the BioLife acquisition.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.15375865 |
| Address1 | Building 1 |
| Address2 | Suite 100 41 Seyon Street |
| All Time High | 327.32 |
| All Time Low | 0.5 |
| Ask | 191.28 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,469,010 |
| Average Daily Volume3 Month | 1,204,400 |
| Average Volume | 1,204,400 |
| Average Volume10Days | 1,469,010 |
| Beta | 1.077 |
| Bid | 163.14 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 37.429 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 175.42 |
| Current Ratio | 9.05 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 177.955 |
| Day Low | 169.73 |
| Debt To Equity | 32.715 |
| Display Name | Repligen |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,102,400 |
| Earnings Call Timestamp Start | 1,793,102,400 |
| Earnings Growth | -0.659 |
| Earnings Quarterly Growth | -0.663 |
| Earnings Timestamp | 1,793,104,200 |
| Earnings Timestamp End | 1,793,104,200 |
| Earnings Timestamp Start | 1,793,104,200 |
| Ebitda | 144,100,992 |
| Ebitda Margins | 0.18354 |
| Enterprise To Ebitda | 67.872 |
| Enterprise To Revenue | 12.458 |
| Enterprise Value | 9,780,429,824 |
| Eps Current Year | 2.06246 |
| Eps Forward | 2.65753 |
| Eps Trailing Twelve Months | 0.73 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 781 250 0115 |
| Fifty Day Average | 173.8174 |
| Fifty Day Average Change | 1.6026001 |
| Fifty Day Average Change Percent | 0.009220021 |
| Fifty Two Week Change Percent | 15.375864 |
| Fifty Two Week High | 198.87 |
| Fifty Two Week High Change | -23.449997 |
| Fifty Two Week High Change Percent | -0.11791621 |
| Fifty Two Week Low | 100.99 |
| Fifty Two Week Low Change | 74.43 |
| Fifty Two Week Low Change Percent | 0.7370037 |
| Fifty Two Week Range | 100.99 - 198.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 515,165,400,000 |
| Float Shares | 53,472,751 |
| Forward Eps | 2.65753 |
| Forward P E | 66.00866 |
| Free Cashflow | 113,421,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,000 |
| Fullday Change | 2.9100037 |
| Fullday Change Percent | 1.6868609 |
| Fullday Price | 175.42 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.53836 |
| Gross Profits | 422,667,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.046630003 |
| Held Percent Institutions | 1.06622 |
| Implied Shares Outstanding | 63,490,365 |
| Industry | Medical Instruments & Supplies |
| Industry Disp | Medical Instruments & Supplies |
| Industry Key | medical-instruments-supplies |
| Ir Website | http://www.repligen.com/investor-relations/shareholder-center |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. |
| Long Name | Repligen Corporation |
| Market | us_market |
| Market Cap | 11,137,479,680 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_33769 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 41,539,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 10,412,936,430 |
| Number Of Analyst Opinions | 20 |
| Open | 172.51 |
| Operating Cashflow | 134,864,000 |
| Operating Margins | 0.09309 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.72 |
| Phone | 781 250 0111 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 175.42 |
| Post Market Time | 1,791,924,296 |
| Previous Close | 172.51 |
| Price Eps Current Year | 85.05377 |
| Price Hint | 2 |
| Price To Book | 4.68674 |
| Price To Sales Trailing12 Months | 14.186048 |
| Profit Margins | 0.05291 |
| Quick Ratio | 7.298 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 2.91 |
| Regular Market Change Percent | 1.68686 |
| Regular Market Day High | 177.955 |
| Regular Market Day Low | 169.73 |
| Regular Market Day Range | 169.73 - 177.955 |
| Regular Market Open | 172.51 |
| Regular Market Previous Close | 172.51 |
| Regular Market Price | 175.42 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 1,259,263 |
| Return On Assets | 0.01395 |
| Return On Equity | 0.0199 |
| Revenue Growth | 0.119 |
| Revenue Per Share | 13.936 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 63,490,365 |
| Shares Percent Shares Out | 0.13430001 |
| Shares Short | 7,581,634 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,612,877 |
| Short Name | Repligen Corporation |
| Short Percent Of Float | 0.1347 |
| Short Ratio | 7.18 |
| Source Interval | 15 |
| State | MA |
| Symbol | RGEN |
| Target High Price | 235.0 |
| Target Low Price | 145.0 |
| Target Mean Price | 196.7 |
| Target Median Price | 200.0 |
| Total Cash | 810,449,024 |
| Total Cash Per Share | 14.361 |
| Total Debt | 690,942,016 |
| Total Revenue | 785,100,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.73 |
| Trailing P E | 240.30136 |
| Trailing Peg Ratio | 1.8399 |
| Triggerable | 1 |
| Two Hundred Day Average | 143.88115 |
| Two Hundred Day Average Change | 31.538849 |
| Two Hundred Day Average Change Percent | 0.2192007 |
| Type Disp | Equity |
| Volume | 1,259,263 |
| Website | https://www.repligen.com |
| Zip | 2,453 |